Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Omeros Shares Rally On Agreement to Sell Omidria Cataract Business

Published 12/03/2021, 12:24 AM
Updated 12/03/2021, 12:24 AM
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Biopharmaceutical firm Omeros Corporation (NASDAQ:OMER) has agreed to the sale of its cataract product Omidria to Rayner Surgical Group Limited in a deal that could ultimately be worth over $1 billion.

Omeros shares surged over 20%. However, they have since given up almost all of those initial gains. 

Rayner will make an upfront payment of $125 million, with a further $200 million paid on the achievement of a commercial milestone. Furthermore, there will be royalties of 50% on U.S. net sales until January 1, 2025, or until the payment of the $200 million milestone — after which royalties will adjust to 30% of U.S. net sales. In addition, there will be royalties on 15% of net sales outside of the U.S.

Rayner will acquire the Omidria commercial organization as part of the agreement, including the sales force, which it plans to expand globally, with the product taking up a key role in Rayner's ophthalmology franchise. 

“OMIDRIA will be an important part of our ophthalmic product portfolio internationally and a key strategic focus for Rayner,” said Tim Clover, CEO of Rayner. “Our new OMIDRIA business and commercial team of seasoned industry professionals are an ideal fit for Rayner as we focus on broadly serving ophthalmic surgeons with our pipeline of innovative products."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.